Prelude Therapeutics (PRLD)
Prelude Therapeutics (PRLD) Stock Price, Analysis & Data
| Bid | 4.11 |
| Market Cap | 458.87M |
| Revenue (ttm) | 22.42M |
| Net Income (ttm) | -60.49M |
| Beta | 0.94 |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.67 |
| P/B (ttm) | 4.43 |
| P/S (ttm) | 20.42 |
| Earnings Date | Nov 11, 2026 |
| Ask | 7.1 |
| Volume | 267,747 |
| Avg. Volume (20D) | 421,724 |
| Open | 5.62 |
| Previous Close | 5.63 |
| Day's Range | 5.49 - 5.78 |
| 52-Week Range | 0.85 - 5.91 |
| Analyst | Strong Buy |
| Price Target | 8 (39.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated ca...
Financial Performance
In 2025, Prelude Therapeutics's revenue was 12.14M, an increase of 73.43% compared to the previous year's 7M. Earnings were -99.5M, a decrease of -21.76%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for PRLD stock is "Strong Buy". The 12-month stock price forecast is 8, which is upside of 39.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
